The Context Renaissance in Pharma
7th UPS Pain in the (Supply) Chain survey sees untapped opportunities in healthcare delivery
Regulatory compliance continues to exceed cost as a primary driver
BioNJ industry survey sees biotech establishment growth but employment decline
A big jump in 2012-2013 venture funding will fuel growth; BMS' new facility
IATA and Brussels Airport seek to build a 'certified community' around cold chain regs for air transport
Airport will organize client carriers to meet new IATA standards
Cold Chain Forum showcases new products, services
Tracking systems dominate product introductions
Omnicare Specialty expands its offices; scores another client
Company is part of limited distribution for a Lundbeck neurologic treatment
IMS Health's top 10 'harbingers of change' in pharmaceutical business
Payer trends dominate near-term outlook
AmerisourceBergen's ThinkLive manufacturer summit highlights an international push
Efforts to align drug wholesaling business with manufacturer services
Software and tech standards advance as pharma traceability deadline looms
GS1 Healthcare US publishes updated track-and-trace guidance; vendors revamp their offerings
Diplomat Pharmacy has a successful IPO, garnering $173 million
Largest independent specialty pharmacy rides specialty-pharma wave
ASD Healthcare's Cubixx system transmits its 400-billionth RFID scan
Vendor-managed system inventories and protects specialty pharmaceuticals in healthcare settings
Drug deliveries by drone--why not?
DHL garners headlines with a 'parcelcopter' delivering daily drugs to remote North Sea island
Simplified approaches to temperature-controlled clinical trial packaging
Often, needless cost and complexity--without improving quality and safety--impede cold chain packaging planning
HHS OIG looks deeply into copay cards for Medicare beneficiaries, finds potential kickback violations
Pharma companies will need to do more than rely on pharmacies' adjudication of claims
A brightening outlook for pharma
The Impending AMP Rule, still waiting three years later
Some state-level changes give an indication of what to prepare for
Economic and clinical value: the future of cancer care
An 'expectations convergence' is building in how drug efficacy aligns with patient outcomes
The potential for outcomes-based contracting
Contracts with payers that contain terms based on outcomes can highlight a drug's value
The next generation of MDM
Clinical trial logistics capabilities are expanding
Service providers are building out a wider range of services to meet drug developers' needs
Outsourcing to innovate: the reinvention of pharma contract services
More complex products and higher risk are changing the nature of pharmaceutical outsourcing
A conversation with Homi Kapadia, Deloitte Life Sciences
The maturing rare-disease market
As rare diseases have emerged as a market opportunity for pharma over the past several years, industry practices are beginning to stabilize
